Part 2/10:
The first topic was the striking announcement from Insight Enterprises regarding a failed Phase 3 clinical trial for its drug, epacadostat, which was tested alongside Merck’s Keytruda for treating melanoma. The study was halted because the combination of the two drugs did not demonstrate any significant improvement over Keytruda alone. This failure not only raises questions about Insight's future but also sends ripples throughout the immunotherapy sector, which has been heavily investing in combination therapies.